Viking Therapeutics (LTS:0VQA) 3-Year EBITDA Growth Rate : -22.20% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Viking Therapeutics 3-Year EBITDA Growth Rate?

Viking Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was $-0.33.

During the past 3 years, the average EBITDA Per Share Growth Rate was -22.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -24.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Viking Therapeutics was 52.60% per year. The lowest was -204.90% per year. And the median was -7.25% per year.

Competitive Comparison of Viking Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Viking Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's 3-Year EBITDA Growth Rate falls into.

Viking Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Viking Therapeutics (LTS:0VQA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Viking Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Viking Therapeutics (LTS:0VQA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (LTS:0VQA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

VKTX:USA 1VT:Germany

Address

9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121

Website

https://www.vikingtherapeutics.com

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics (LTS:0VQA) Headlines

No Headlines